Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclonal antibodies have the potential to be identified by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE). Therapeutic antibody interference with standard clinical SPE and IFE can confound the use of these tests for response assessment in clinical trials and disease monitoring. To discriminate between endogenous myeloma protein and daratumumab, a daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) was developed using a mouse anti-daratumumab antibody. To evaluate whether anti-daratumumab bound to and shifted the migration pattern of daratumumab, it was spiked into daratumumab-containing serum and resolved by IFE/SPE. The presence (DIRA positive) or absence (DIRA negative) of residual M-protein in daratumumab-treated patient samples was evaluated using predetermined assessment criteria. DIRA was evaluated for specificity, limit of sensitivity, and reproducibility. In all of the tested samples, DIRA distinguished between daratumumab and residual M-protein in commercial serum samples spiked with daratumumab and in daratumumab-treated patient samples. The DIRA limit of sensitivity was 0.2 g/L daratumumab, using spiking experiments. Results from DIRA were reproducible over multiple days, operators, and assays. The anti-daratumumab antibody was highly specific for daratumumab and did not shift endogenous M-protein. As the treatment of myeloma evolves to incorporate novel monoclonal antibodies, additional solutions will be needed for clinical monitoring of patient responses to therapeutic regimens. In the interim, assays such as DIRA can inform clinical outcomes by distinguishing daratumumab from endogenous M-protein by IFE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1×
“As a human IgGκ immunoglobulin, daratumumab may be detected by IFE and can thus be misinterpreted as a myeloma-associated M-protein, thereby interfering with the response criteria [19].”
BackgroundInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 4×
“To evaluate the amount of anti-daratumumab needed to Brought to you by | University Library of Southern Denmark - Syddansk Universitetsbibliotek Authenticated Download Date | 1/8/18 1:53 PM completely shift daratumumab on IFE and SPE, varying ratios of anti-daratumumab were spiked into serum containing 1 g/L daratumum…”
BackgroundInfluentialElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 2×
“Phase 1 and 2 studies of daratumumab as a monotherapy have yielded deep responses, including CRs and sCRs [6, 8], making it essential to establish a reliable method for distinguishing M-protein from daratumumab.”
BackgroundMethodSelf-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 3×
“SIRIUS, a phase 2 study, examined daratumumab in patients with at least three lines of prior therapy or double refractory MM [8].”
BackgroundMethodSelf-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 1×
“completely shift daratumumab on IFE and SPE, varying ratios of anti-daratumumab were spiked into serum containing 1 g/L daratumumab, the maximum predicted concentration in patient serum after weekly dosing [15].”
MethodDaratumumab: First Global Approval
McKeage, K. (2016) · Drugs · doi:10.1007/s40265-015-0536-1 · Cited by 120
Clarification of the definition of complete response in multiple myeloma
Durie, B. G. M., Miguel, J. F. S., Blade, J., Rajkumar, S. V., & on behalf of the International Myeloma Working Group (2015) · Leukemia · doi:10.1038/leu.2015.290 · Cited by 42 · cited 4×
“At the recommended dosing schedule (16 mg/kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and every 4 weeks thereafter), daratumumab reaches peak serum concentrations of approximately 915 μg/mL (0.915 g/L) at the end of the weekly dosing period [18], making it readily detectable on most SPE/IFE assays [1].”
BackgroundInfluential
Research works printed but not linked: 34
- 2014, Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma, Cancer Res, 74
- 2012, Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking, Blood, 120
- 2015, Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma, Blood, 126
- 2016, Daratumumab: first global approval, Drugs, 76, 275, 10.1007/s40265-015-0536-1 · DOI · Paper page
- 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 · DOI · Paper page
- 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
- 2015, Targeting CD38 with daratumumab monotherapy in multiple myeloma, N Engl J Med, 373, 1207, 10.1056/NEJMoa1506348 · DOI · Paper page
- Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
- 2015, Elotuzumab therapy for relapsed or refractory multiple myeloma, N Engl J Med, 373, 621, 10.1056/NEJMoa1505654 · DOI · Paper page
- 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 · DOI · Paper page
- 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
- 2015, Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma, Blood, 126
- 2014, Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma, Cancer Res, 74
- 2016, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial, Lancet
- 2013, Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation, Clin Biochem, 46, 255, 10.1016/j.clinbiochem.2012.10.030 · DOI
- 2011, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, J Immunol, 186, 1840, 10.4049/jimmunol.1003032 · DOI · Paper page
- 2013, Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation, Clin Biochem, 46, 255, 10.1016/j.clinbiochem.2012.10.030 · DOI
- Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
- 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
- 2015, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, MAbs, 7, 311, 10.1080/19420862.2015.1007813 · DOI · Paper page
- 2015, Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody, J Clin Oncol, 33
- 1998, Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation, Blood, 91, 3518, 10.1182/blood.V91.9.3518 · DOI
- 2012, Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking, Blood, 120
- 2015, Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody, J Clin Oncol, 33
- 2011, Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis, Br J Haematol, 155, 123, 10.1111/j.1365-2141.2011.08644.x · DOI
- 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
- 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 · DOI · Paper page
- 2015, Clarification of the definition of complete response in multiple myeloma, Leukemia, 29, 2416, 10.1038/leu.2015.290 · DOI · Paper page
- Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
- 1998, Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation, Blood, 91, 3518, 10.1182/blood.V91.9.3518 · DOI
- 2010, Interference of monoclonal antibody therapies with serum protein electrophoresis tests, Clin Chem, 56, 1897, 10.1373/clinchem.2010.152116 · DOI · Paper page
- Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
- 2010, Interference of monoclonal antibody therapies with serum protein electrophoresis tests, Clin Chem, 56, 1897, 10.1373/clinchem.2010.152116 · DOI · Paper page
- 2011, Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis, Br J Haematol, 155, 123, 10.1111/j.1365-2141.2011.08644.x · DOI
Cited by
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citation
Metadata
- Authors
- McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T., & Sasser, A. K.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2016-01-01
- Volume
- 54
- Issue
- 6
- Pages
- 1095-104
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2325601336
- Cited by
- 124
- References
- 10
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. https://app.cochat.ai/papers/10.1515/cclm-2015-1031
- The paper
- McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T., & Sasser, A. K. (2016). Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2015-1031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.